Literature DB >> 6650196

Piracetam modifies morphine and related drug-induced elevation of serum corticosterone concentration in rats.

L Korányi, E Endröczi.   

Abstract

Piracetam (2-oxo-l-pyrrolidine acetamide, UCB 6215) or physiological saline solution was injected intravenously to female rats; after 60 min the animals were decapitated and blood was collected. Piracetam in doses of 100, 300 and 600 mg/kg resulted in a progressive suppression of serum corticosterone concentration (Cpd B) as compared to the controls. Morphine (5 and 10 mg/kg), nalorphine (5 and 10 mg/kg) and naloxone (0.5 mg/kg) induced a significant rise of Cpd B 30 min after subcutaneous injection, however, this could be prevented by 300 mg/kg piracetam given intraperitoneally 60 min prior to decapitation. Piracetam was ineffective in reducing the effects of high doses of morphine (20 mg/kg) and nalorphine (20 mg/kg). The drug had no effect on either ether stress or electric footshocks induced activation of the pituitary-adrenocortical system. In vitro the drug had no effect on pituitary ACTH release following exposure to crude hypothalamic extract. It is concluded that the effect of piracetam on the pituitary-adrenocortical axis is mediated through hypothalamic or extrahypothalamic brain structures and influences one of the effects of morphine and related drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6650196

Source DB:  PubMed          Journal:  Acta Physiol Hung        ISSN: 0231-424X


  2 in total

1.  Transgenerational blunting of morphine-induced corticosterone secretion is associated with dysregulated gene expression in male offspring.

Authors:  Fair M Vassoler; Anika M Toorie; Elizabeth M Byrnes
Journal:  Brain Res       Date:  2017-11-10       Impact factor: 3.252

2.  Modulating effect of the nootropic drug, piracetam on stress- and subsequent morphine-induced prolactin secretion in male rats.

Authors:  A Matton; S Engelborghs; F Bollengier; E Finné; L Vanhaeist
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.